Related Experiment Video

Updated: Jun 28, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

NCCN Task Force Report: mTOR inhibition in solid tumors

Robert A Figlin, Elizabeth Brown, Andrew J Armstrong

    Journal of the National Comprehensive Cancer Network : JNCCN
    |November 15, 2008
    PubMed

    Insights

    Targeting the mammalian target of rapamycin (mTOR) pathway offers a promising strategy for cancer treatment. mTOR inhibitors are being investigated in various solid tumors to combat cancer progression and drug resistance.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Signaling

    Background:

    • The mammalian target of rapamycin (mTOR) protein complex integrates signaling pathways crucial for cell cycle, proliferation, and angiogenesis.
    • Dysregulation of these pathways is common in cancer, making mTOR inhibition a significant therapeutic target.
    • Current mTOR inhibitors include rapamycin, temsirolimus, everolimus, and deforolimus.

    Purpose of the Study:

    • To review the physiology of mTOR and related cellular pathways.
    • To summarize the current research status of mTOR inhibition in solid tumors.
    • To address the complexities of mTOR pathway dysregulation in malignancies.

    Main Methods:

    • Review of preclinical studies and early-phase clinical trials.
    • Analysis of mTOR inhibition as monotherapy and in combination regimens.
    • Expert task force convened by NCCN to synthesize current research.

    Main Results:

    • mTOR inhibition is explored in breast, gynecologic, gastrointestinal, prostate, lung, and head and neck cancers.
    • Combination therapies aim to reduce drug resistance by inhibiting multiple targets.
    • Temsirolimus is the only currently FDA-approved mTOR inhibitor for solid tumors.

    Conclusions:

    • mTOR inhibition represents a key strategy in solid tumor treatment.
    • Ongoing research continues to define mTOR pathway complexities and therapeutic applications.
    • Further investigation is needed to optimize mTOR-targeted therapies in oncology.

    More Related Videos

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

    Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

    Published on: April 29, 2014

    Related Concept Videos

    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...